Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

Stock code: 300957 Stock abbreviation: Botanee Announcement number: 2026-011

Yunnan Botanee Bio-Technology Group Co. Ltd.Summary of the 2025 Annual Report

I. Important Notice

(1) This annual report summary is derived from the full text of the annual report. To fully

understand the Company’s operating results financial status and future development plans

investors should carefully read the full annual report on the media designated by the China

Securities Regulatory Commission.

(2) All directors attended the Board meeting for deliberating on this report.

(3) Tianheng Certified Public Accountants (Special General Partnership) issued a standard

unqualified opinion on the Company’s financial report for the year.Notice of the non-standard audit opinion

□ Applicable □Not applicable

The Company was not profitable at the time of its listing and has not achieved profitability to date

□ Applicable □Not applicable

Profit distribution plan or capital reserve transfer plan to increase capital approved by the board

during the reporting period

□Applicable □ Not applicable

The profit distribution plan approved by the Board during this meeting is: Based on the Company’s

total share capital of 423600000 shares subtracting 2307118 shares in the repurchase special

account that do not participate in the profit distribution i.e. using 421292882 shares as the base a

cash dividend of CNY3.50 (tax included) will be distributed for every 10 shares to all shareholders

with 0 bonus share (tax included) and 0 share for every 10 shares transferred to all shareholders

from capital reserve.The profit distribution plan for preferred shares approved by the Board during the reporting period

□ Applicable□Not applicable

II. Company Overview

1. Company Profile

Stock name Botanee Stock code 300957

Stock listing exchange Shenzhen Stock Exchange

Contact person and contact information Board Secretary Securities representative

Name Wang Long Xu Minjing

Office address No. 53 Keyi Road Kunming High-tech No. 53 Keyi Road Kunming High-techIndustrial Development Zone Kunming Industrial Development Zone Kunming

1Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

Yunnan Province Yunnan Province

Fax 021-6232 1125 021-6232 1125

Tel. 021-6232 1125 021-6232 1125

Email ir@botanee.com ir@botanee.com

2. Overview of Main Business or Products During the Reporting Period

2.1 Company’s Main Business and Products

Yunnan Botanee Bio-Technology Group Co. Ltd. (hereinafter referred to as the “Company”)

focuses on the development of multiple brands including core brand Winona as well as Winona

Baby AOXMED Beforteen Za PURE&MILD and TriPollar1. We specialize in providing

professional and effective skincare products using pure natural plant-derived active ingredients

with a particular emphasis on sensitive skin. As a specialized cosmetics manufacturer that integrates

deeply with internet- based sales channels our mission is to “create China’s skin health ecosystem”

by deeply understanding consumer needs basing its products on dermatological theories and

combining multidisciplinary technologies such as biology and botany to continuously conduct

product research and technological innovation. We strive to provide professional skincare medical

devices and makeup products that cater to different skin needs.We have established a foundation through offline pharmaceutical channels and implemented an

omnichannel strategy covering online platforms. With a comprehensive retail touchpoint system we

have successfully realized cross-industry marketing (OMO) leveraging the internet and new

technologies like artificial intelligence. This has facilitated mutual penetration between offline and

online channels and achieved extensive coverage of consumer groups which makes Botanee a

leading company in the internet+ greater health industry in China. Additionally we capitalize on the

efficiency of the internet the vast user traffic on mainstream e-commerce platforms and flexible

new media marketing methods. With our strengths in online operations and high-quality products

we have successfully seized the opportunities for rapid growth in the cosmetics industry driven by

the “Chinese domestic products” trend.Our main product categories include facial creams toners face masks serums lotions as well as

makeup products such as sunscreens powders BB creams and makeup removers. In addition to

skincare and makeup we are also engaged in the research development production and sales of

medical devices and electronic beauty devices related to skincare. This includes medical devices

and home-use electronic radio frequency (RF) beauty devices such as hyaluronic acid repair biofilm

and hyaluronic acid repair dressings used for the protection and care of damaged skin barriers after

minimally invasive procedures.

1 TriPollar is limited to the Chinese mainland; the same below.

2Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

2.2 Main Brand Matrix

Winona

Winona protects sensitive skin with professional expertise and studies Yunnan’s unique plants

based on dermatological research. Empowered by technology and evidence-based support Winona

offers professional precise and safe efficacy-driven skincare solutions for sensitive skin.Winona Baby

Inheriting the genetic essence of the parent brand Winona Winona Baby collaborates with pediatric

dermatology experts to develop effective skincare products for babies and focuses on the eczema

treatment sector for infants and toddlers. Based on dermatological expertise and clinical experience

Winona Baby offers a professional infant and toddler skincare brand with a simplified ingredient

and exclusive patented plant extract formulas.

3Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

AOXMED

Born for professional beauty focusing on skin rejuvenation and linking medical aesthetics with

home beauty AOXMED offers effective and safe in-clinic medical beauty and cosmetic care

combined with home-based medical-grade sequential skincare while advocating for mindfulness in

youthfulness and promoting the right approach to prevent skin aging achieving holistic anti-aging

for both body and mind.Beforteen

Beforteen collaborates with dermatological experts to conduct case studies on over one millioncases integrating AI consultations and providing personalized unique and integrated “food +medicine +cosmetics” solutions for the precise treatment of different types of acne.

4Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

Za

Za focuses on the characteristics of Asian women’s skin and offers high-performance base makeup

solutions that are multi-functional and easy to use. Za is positioned as an international light makeup

brand that allows users to effortlessly enjoy their beautiful daily life. The core products of Za

include base makeup products such as four-color sunscreen tinted moisturizer powders and oil

cleanser. Its star product the sunscreen has been a bestseller internationally for 22 years.PURE&MILD

As a skincare brand designed specifically for Chinese women PURE&MILD carefully selects rare

plants from around the world and combines advanced skincare technologies and effective

ingredients to offer consumers a gentle yet long-lasting plant-based skincare solution that

5Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

rejuvenates the skin. The core products of PURE&MILD include toners lotions and facial creams

and the brand has been operating for 25 years.TriPollar

Specializing in bringing professional anti-aging solutions from clinical settings to home use

TriPollar leverages Lumenis’ over 50 years of clinic aesthetic medical technology while deeply

integrating Botanee’s dermatological science expertise. With professional energy-based medicine

technology at its core TriPollar creates a synergistic home repair and anti-aging solution that

combines “clinical energy with photoelectric-specific skincare”. As a dermatology-grade brand

dedicated to at-home clinical anti-aging it delivers a safe and efficient home anti-aging experience

for users.

2.3 Review of MajorAccomplishments in 2025

During the reporting period facing multiple challenges such as the slow recovery of the consumer

market intensified industry competition rising online traffic costs and profound adjustments inchannel structure Botanee adhered to the core strategy of creating a skin health ecosystem”. Guided

by “one center and two basic points” (with brand building as the center and member operation and

omnichannel synergistic growth as the basic points) the Company achieved comprehensive

breakthroughs in areas such as brand upgrading product innovation intensive channel cultivation

tackling key R&D challenges digital transformation supply chain quality improvement and

organizational reform. As a result overall operations remained steady the multi-brand matrix

generated synergistic effects and the positive momentum of high-quality development in core

businesses has continued to solidify.

2.3.1 Continuously deepen brand and academic development to consolidate the leading

position in dermatology

During the reporting period the Company built a comprehensive marketing matrix fully shifting

from pursuing “exposure” to deeply cultivating “brand equity accumulation” ensuring the

consistency of user experience by unifying brand personality and language. During the reporting

6Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Reportperiod Winona officially established its brand image as a “professional dermatology expert +radiant lifestyle expert” and clarified the original aspiration of returning to “beauty stems fromhealth”. During the reporting period the core products of Winona maintained strong performance:

The “Winona Sensitiveness Relieving Moisturizing Tolerance-Extreme Cream” series once again

ranked first in sales within the sensitive skin cream segment. The “Winona Sunblock Milk” series

further increased its market share establishing a refined scenario matrix covering needs from daily

commuting to outdoor activities. The Camellia-Lucent series saw steady growth among which the

set of Camellia-Lucent Correcting Essence Lotion and Luminous Brightening Radiance Repair

Emulsion ranked TOP 1 among new toner and lotion products on Douyin. In addition during the

reporting period Winona successfully pioneered a new anti-aging track for sensitive skin launching

the flagship “Silver Core” series anti-aging solution which attracted significant market attention

upon its debut. Meanwhile the newly upgraded Barrier Repair Essence (311 Single-Pulse Essence)

series rapidly ranked among the TOP 10 in the single-pulse essence category on Tmall.During the reporting period the Company continued to strengthen the core strategy of “medicalempowerment of brands” systematically constructed and elaborated the scientific theoretical

system of its brands and products through the white paper Advancing the High-Quality

Development of Efficacy Skincare Products in China Following the NUTE Principle2 officially

released at the 6th China Sensitive Skin Summit and completed the development of two major core

knowledge bases. During the reporting period the Company actively participated in the Annual

Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology andcontinued to increase investment in public welfare projects such as the “525 Scientific SkincareWeek” and “919 Acne Week” demonstrating and conveying the medical empowerment capabilities

of Botanee’s brands through forms such as professional endorsements skin health education and

professional free clinics. Internationally the Company was the only Chinese brand invited to attend

the 4th ILDS World Skin Summit and actively participated in the drafting of the world’s first

consensus on visible light protection. This marks a milestone where the Company has made China’s

voice heard at the global dermatology decision-making level.

2.3.2 Mature the brand matrix to drive synergistic growth across differentiated tracks

During the reporting period Winona Baby achieved high-quality growth. By focusing on solutions

for infant and toddler eczema it realized a sales revenue of CNY234725300 representing a year-

on-year increase of approximately 17.02%. Notably revenue on the Douyin platform surged by

approximately 109.56%. Winona Baby successfully entered premium offline KA channels such as

Sam’s Club and Watsons. The core products “Soothing Hydrating Cream” and “Mild MulticareSunscreen both achieved steady growth while the new products “Xiaobingdun” (Prinsepia Utilis

Microcapsule Soothing Cooling Essence Gel) and “Nuanrongrong” (Multi-Effect Plant-Based

Soothing and Moisturizing Cream) face creams became instant hits upon launch firmly securing its

position in the first tier of functional skincare for infants.During the reporting period AOXMED achieved a milestone breakthrough with sales revenue

growing over 100.00% year-on-year. Revenue from online channels surged approximately 140.90%

year-on-year successfully marking the brand’s leap “from 0 to CNY100 million”. During thereporting period AOXMED adopted a core strategy of “full-process anti-aging combining medical

2 The NUTE scientific principles which underpin the high-quality development of functional skincare products mainly

comprise four aspects:

Need: Starting from addressing key pain points and unmet needs;

Unique: New mechanisms new targets and new outcomes;

Technology: Innovation in ingredients formulations and technologies;

Evidence: Based on clinical observations with real-world efficacy validation.

7Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Reportbeauty and cosmetics” and partnered with over 600 professional clinic-based institutions

nationwide. Its premium anti-aging brand image has become deeply rooted in the market.During the reporting period Beforteen continued to center on its core proposition of “AI-poweredprecision and effective acne treatment” intensifying its presence on social platforms like

Xiaohongshu with over 320 million exposures. This successfully established the association

between “Beforteen = Graded Acne Treatment” in user mindset. During the reporting periodBeforteen successfully achieved an increase in the repurchase rate through the “medicine +cosmetics” solution and Internet medical services.During the reporting period the Company successfully acquired TriPollar laying a solid foundation

for its strategic layout in the fields of medical devices and home beauty devices. During the

reporting period TriPollar achieved a leap in ranking from Top 15 to Top 5 in the high-end home

RF beauty device market. In the future TriPollar will rebuild the “facial anti-aging + eye anti-aging”

product matrix leveraging the Company’s end-to-end quality control system and the operationalcapabilities of an omnichannel marketing closed loop to re-establish the image of “the leader inbringing clinical anti-aging to home use” in user mindset.During the reporting period Za and PURE&MILD achieved steady operations under the

Company’s empowerment. Za has launched high-quality products across Chinese Mainland Taiwan

of China Hong Kong of China and Singapore covering a diverse range of beauty categories

including makeup primers base makeup eye and lip products and finishing products. The brand’

s hero product its makeup primer achieved full-channel exposure through official announcements

featuring brand ambassadors and IP collaborations and ranked No.1 on Tmall’s best-selling list

for oil-control primers. PURE&MILD partnered with a Yunnan Specialty Plant Extraction

Laboratory to conduct research on BotanSTB Plus for anti-photoaging with the findings

successfully published in an international academic journal. In 2025 leveraging the Key Laboratory

of Applied Enzymology at the Yangtze River Delta Institute of Tsinghua University PURE&MILD

integrated AI-powered computational biotechnology with biopharmaceutical-grade manufacturing

technologies to incorporate its patented recombinant Type XXI collagen into the upgraded Collagen

Bouncy Anti-Wrinkle Cream 2.0 for the first time delivering full-path anti-aging efficacy. Shortly

after its launch Collagen Bouncy Anti-Wrinkle Cream 2.0 ranked among the Top 10 most popular

anti-aging creams on Douyin Mall.

2.3.3 Cultivate channel excellence and driving synergistic omnichannel deployment

During the reporting period facing online traffic fragmentation and offline foot traffic challenges

the Company actively promoted channel transformation and refined operations. While solidifying

its position in online channels the Company saw particularly impressive performance from

emerging instant retail channels. Winona firmly maintained its top position in the functional

skincare industry within the OTC retail pharmacy channel expanding its coverage by over 3500

chain retail pharmacies. During the reporting period the Company fully committed to its instant

retail channel expansion. By leveraging the mature distribution networks of KA channel partners

alongside its own branded counters it made a strong entry into O2O platforms securing the No. 1

position in the skincare brand category on Meituan’s instant retail business. This enabled the

Company to successfully capture the traffic dividends from both the nighttime economy and on-

demand sensitive skin scenarios.During the reporting period the Company continuously optimized its online channel structure.Despite pressure on gross merchandise value in shelf-based e-commerce the Company achieved a

significant increase in gross profit margin driven by the strong performance of influencer

livestreaming with the sales gross margin rising by approximately 2.70 percentage points year-on-

8Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

year. Content-driven e-commerce benefited from customized marketplace operations and the

establishment of an influencer distribution system delivering a year-on-year revenue growth of

approximately 17.25%. During the reporting period the Company also implemented more refined

operations across different platforms and cities driving impressive growth in lower-tier channels

including Pinduoduo private domains and distribution while maintaining a top-tier industry

position on JD.com and Vipshop.During the reporting period the Company steadily expanded its overseas markets. Through multiple

models including self-operated distribution and agency channels it established a presence in Hong

Kong SAR Macao SAR Taiwan region and multiple countries and regions in Southeast Asia and

North America. The pace of brand internationalization has been continuously accelerating and

intensifying.

2.3.4 Continuously enhance R&D and innovation and build a deep moat with hardcore

technologyDuring the reporting period the Company continued to adhere to the R&D philosophy of “TargetedFocus In-Depth Research Real Results” and achieved milestone breakthroughs across

fundamental research raw material innovation medical devices and global expansion.During the reporting period the Company continued to deeply engage in the innovative research

and development of new cosmetic raw materials adding five new cosmetic raw material filings

during the year and bringing the cumulative number of filings to 17. The Company’s filing scale

firmly ranked first nationwide leading the industry’s raw material innovation track. Relying on the

endowment of Yunnan’s plant resources the Company independently completed the research and

development of 43 cosmetic raw materials and eight food raw materials among which the

whitening raw material BTN-737 developed based on YKMB-002 and AI generative design was

successfully included in the innovation service catalog of the National Institutes for Food and DrugControl. The self-developed raw materials won two prestigious awards， namely the “InnoCosmeAwards 2025 for Raw Materials” and the “China Innovative Raw Material Award”. In terms of

global expansion the Company successfully participated in In-Cosmetics Global the world’s top

professional exhibition for cosmetic raw materials making the international debut of its self-

developed raw materials. It showcased 11 proprietary ingredient products demonstrating to the

global industry the innovative strength of Chinese beauty ingredients.During the reporting period the Company completed the filing of 31 general cosmetics products

and the registration of 10 special cosmetics products. To support overseas market expansion the

Company also completed 13 export filings covering regions including North America Europe the

Middle East and Southeast Asia thereby laying a solid compliance foundation for the global

expansion of its brands. During the reporting period the Company obtained seven new Class II

medical device registration certificates which feature sodium hyaluronate and recombinant

collagen as core components and cover various dosage forms such as liquids gels lotions creams

and dressings further improving the synergistic product ecosystem featuring medical device and

cosmetics. Meanwhile the Company achieved a breakthrough in Class III medical devices marking

a milestone for Class III implantable medical devices. Both “BTN001” and “BTN002” successfully

passed registration testing clinical trials and quality system inspections and have entered the

review stage of the National Medical Products Administration. In addition a third filler-type

medical device has initiated registration testing.In terms of global scientific research cooperation during the Reporting Period the Company

established a long-term Ph.D. training partnership with Saint-Louis Hospital in France. It also

deepened its research collaboration with University of Paris-Saclay on the molecular mechanisms of

neurocosmetics. In partnership with Labskin Creations the Company co-developed two proprietary

9Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

3D skin models which were presented at the Annual Meeting of the European Society for

Dermatological Research. Furthermore the Company entered into a strategic partnership with an

organ-on-a-chip company affiliated with MIT jointly exploring the application of organoids and

organ-on-a-chip technologies in cosmetic evaluation.During the reporting period the Company was granted 50 invention patents 16 utility model

patents and three design patents. It also participated in the formulation and release of four national

standards and 10 group standards and initiated the R&D of one national standard sample. During

the reporting period the Company published 160 academic papers including 115 SCI-indexedpapers and 45 papers in Chinese core journals. During the reporting period the “R&D andIndustrialization of Domestic Efficacy Skincare Products” project was shortlisted in the public

notification list for the Special Prize of the 2025 Yunnan Provincial Science and Technology Award

“R&D and Industrial Application of Winona Efficacy Skincare Products for Sensitive Skin” won

the First Prize of the Science and Technology Progress Award of the China National Light IndustryCouncil and the Company’s core brand Winona was selected into the first batch of “ChinaPremium Consumer Brands” by the Ministry of Industry and Information Technology.

2.3.5 Improve supply chain quality and efficiency and deepen green and low-carbon

developmentDuring the reporting period the Company’s supply chain system focused on “digital and intelligentempowerment supply and demand balance quality improvement and efficiency enhancement”

achieving remarkable results. The Company’s proportion of independent production continued to

increase steadily effectively ensuring the capacity release of self-operated factories and the stability

of product gross profit margins. By deepening the S&OP mechanism and lean management

inventory turnover efficiency was significantly optimized by approximately 16.97% year-on-year.In addition the Company implemented product lifecycle management. As of the end of the

reporting period the number of long-tail and inefficient inventory products was reduced by nearly

50% and operational efficiency was significantly improved.

2.3.6 Fully empower the significant enhancement of operational efficiency with digitalization

and AIDuring the reporting period the Company’s Digital Technology Center transitioned from “buildingplatforms” to “creating value”. The Company’s internal AI platform ChatBTN was successfully

launched covering core business scenarios across multiple departments. The Consumer Data

Platform (CDP) was fully launched and data extraction efficiency improved from the “day” level to

the “minute” level. The integrated business and finance platform was fully established achieving

the same source of business and financial data as well as procedure connectivity. During the

reporting period the membership middle platform achieved remarkable results. The Company’s

total registered members across all channels surpassed 46 million representing a year-on-year

increase of approximately 10%. Leveraging the consumer data platform the retention rate of

existing members increased by approximately 8% and the conversion rate of new members

increased by approximately 5%. During the reporting period the Company released its first

Member Points White Paper driving the member points system from extensive operations toward

intelligent risk control and precision marketing. During the reporting period the Company’s self-

developed supply chain planning and management platform was launched initially realizing the

deployment of over 20 smart scenarios including AI-powered intelligent inspection and automated

replenishment.

2.3.7 Insist on the long-term ESG strategy and practice green low-carbon development and

business for good

10Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual ReportDuring the reporting period guided by the philosophy of “all for the health and beauty of humansand nature” the Company deeply integrated ESG into its strategy. Leveraging Yunnan’ s rich

botanical resources it has built a closed-loop model combining ecological conservation with green

industrialization setting a benchmark for sustainability in the beauty industry. In terms of

environmental aspect the Company continues to advance biodiversity conservation establishing

approximately 10.42 mu of ecological demonstration plots in the Hutiao Gorge area and carrying

out the reintroduction of rare alpine plant species to strengthen mountain ecosystem resilience. In

clean energy the central factory generated approximately 1.59 million kWh of solar power for self-

consumption annually. Significant progress was made in green packaging reduction with 3.5484

million inner boxes and 2.106 million paper leaflets eliminated during the year alongside the

recycling of 3.17 million empty bottles. RSPO-certified raw materials accounted for approximately

58% of procurement with a material substitution rate of 96%. The Company also optimized its

warehousing and logistics network by promoting new energy transportation and energy-efficient

storage and continued to conduct full lifecycle carbon footprint assessments to drive emissions

reduction across the value chain. In terms of social aspect the Company remains committed to

public welfare. During the reporting period it contributed CNY13.678 million (including cash andin-kind donations) supporting 31 initiatives. The Company has continued its “Winona SmileSunshine Program” for the 10th consecutive year conducting free medical consultations and

public education campaigns in high-UV regions such as Shangri-La. The “Winona Baby” brand

also advanced its public welfare initiative supporting children with atopic dermatitis (AD) reaching

over 180 million people through educational outreach. Meanwhile the Company has fostered an

inclusive workplace with women accounting for 56% of management positions and has placed

strong emphasis on talent development with employees receiving an average of over 108 training

hours per year. In terms of governance aspect the Company has maintained an A rating for

information disclosure from the Shenzhen Stock Exchange for the third consecutive year. During

the reporting period it was included in Wind’ s Top 100 Best ESG Practices among Chinese’s

Listed C0ompanies and received an “AA” ESG rating. It was also recognized among the TOP

100 A-share listed companies for ESG excellence by Sino-Securities Index achieving the highest

“AAA” rating. Looking ahead the Group will continue to empower ecological development

through technology and uphold a long-term approach expanding its sustainable mountain

ecosystem model and delivering an Eastern approach to green beauty solutions to the global market.

2.4 Overview of Overall Performance in 2025

During the reporting period the Company actively responded to the complex and changing market

environment striving to overcome various adverse factors and achieved certain results in its

operational performance. During the reporting period the Company achieved operating revenue of

approximately CNY5358638800 a year-on-year decrease of approximately 6.58%; a net profit

attributable to the shareholders of the listed company of approximately CNY505719700 a slight

year-on-year increase of approximately 0.53%; a net profit attributable to the shareholders of the

listed company after excluding non-recurring gains and losses of approximately CNY356146600

a significant year-on-year increase of approximately 48.22%; a sales gross profit margin of

approximately 74.46% a year-on-year increase of approximately 0.72 percentage points; and a net

sales margin attributable to shareholders of the listed Company of approximately 9.44% a year-on-

year increase of approximately 0.67 percentage points. During the reporting period although the

Company’s sales volume declined slightly profits (gross profit and net profit) showed a steady

trend and profitability has improved with recurring profit achieving a more significant

improvement. During the reporting period fluctuations in the Company’s revenue and profit were

primarily attributable to a combination of the following factors: First increased investment in brand

building channel development and marketing expenses to consolidate the Company’s market

11Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

position and incubate new brands and products; second strategic investments to respond to market

changes and channel transformation including the active expansion of new growth drivers such as

instant retail and content-driven e-commerce; third necessary expenditures to enhance the

autonomy and controllability of supply chain and to strengthen product innovation. In addition

asset impairment provisions resulting from the underperformance of acquired targets relative to

expectations also had a certain impact on performance. Meanwhile during the reporting period the

Company’s cash flow remained healthy the quality and efficiency of operating cash flow further

improved and operating fundamentals were solid. Looking ahead the Company will stay

committed to long-termism focus on its advantageous segments and strengthen omnichannel

synergy. By continuously driving cost reduction and efficiency enhancement organizational

transformation and refined operations the Company aims to achieve both healthy brand

development and higher profit quality facilitating its transition from scale-driven growth to value-

driven growth.

3. Key Accounting Data and Financial Indicators

3.1 Key Accounting Data and Financial Indicators for the Last Three Years

Whether the Company retrospectively adjusted or restated accounting data for previous year

□ Yes□No

Unit: CNY

YoY

End of 2025 End of 2024 increase/decreasecompared with the End of 2023

previous year

Total assets 8341346880.58 8303551892.22 0.46% 7506930342.79

Net assets attributable to our

shareholders 6157265024.87 6049901389.45 1.77% 5860994371.02

YoY

2025 2024 increase/decreasecompared with the 2023

previous year

Operating revenue 5358638784.56 5735865254.21 -6.58% 5522168263.00

Net profit attributable to our

shareholders 505719663.85 503053586.13 0.53% 756795007.56

Net profit attributable to our

shareholders after deducting non- 356146562.10 240289033.33 48.22% 618058791.53

recurring gains and losses

Net cash flow from operating

activities 976595739.84 694865456.23 40.54% 610438763.71

Basic earnings per share

(CNY/share) 1.20 1.20 No change 1.79

Diluted earnings per share

(CNY/share) 1.20 1.20 No change 1.79

Weighted average return on net 8.20% 8.53% Decreased by 0.33assets percentage points 13.21%

3.2 Key Accounting Data by Quarter

Unit: CNY

Q1 Q2 Q3 Q4

12Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

Operating revenue 948763070.82 1423079513.94 1092432006.28 1894364193.52

Net profit attributable to our

shareholders 28340519.25 218320285.14 25217931.45 233840928.01

Net profit attributable to our

shareholders after deducting non- 20924775.03 161692314.46 1148777.26 172380695.35

recurring gains and losses

Net cash flow from operating

activities -68652234.98 415580994.65 94950854.20 534716125.97

Whether the aforesaid financial indicators or their sum are significantly different from relevant

financial indicators disclosed by the Company in its quarterly and semi-annual reports

□ Yes□No

4. Share Capital and Shareholder Information

4.1 Number of Ordinary Shareholders and Preferred Shareholders with Restored Voting

Rights and the Shareholding of the Top 10 Shareholders

Unit: share

Total Total Total number

number of number of of preferred

Ordinary ordinary preferred shareholdersshareholders shareholders with restored Shareholdersshareholders

as of the at the end of with voting rights as

holding

end of the 40048 the month 35462 restored of the end of

special

reporting prior to the voting the month

voting

period disclosure rights at the prior to the

shares (if

of the end of the disclosure of any)

annual reporting the annual

report period report

Shareholding of the top 10 shareholders (excluding shares loaned through refinancing)

Number Pledged marked or

Shareholding Number of of shares frozen sharesShareholder name Shareholder type ratio shares held subject totrading Status of Quantity

restriction shares

Kunming Nuona Technology Co. Domestic non-state-

Ltd. owned corporation 45.97% 194743411.00 N/A

Tianjin Sequoia Juye Equity

Investment Partnership (Limited Domestic non-state-

Partnership) owned corporation

7.62% 32272757.00 N/A

Yunnan Haqisheng Enterprise Domestic non-state-

Management Co. Ltd. owned corporation 2.60% 10993678.00 N/A

Xiamen Zhenli Consulting Co. Ltd. Domestic non-state-owned corporation 2.47% 10467669.00 N/A

Hong Kong Securities Clearing Overseas legal

Company Limited person 1.29% 5445491.00 N/A

Kuwait Investment Authority Overseas legalperson 1.04% 4390658.00 N/A

Industrial and Commercial Bank of

China Co. Ltd. — E Fund GEM

Traded Open-End Index Securities Miscellaneous 0.86% 3663991.00 N/A

Investment Fund

National Social Security Fund

Portfolio 118 Miscellaneous 0.81% 3417711.00 N/A

Industrial and Commercial Bank of

China Limited — CSI Main

Consumer Exchange-Traded Open- Miscellaneous 0.73% 3084657.00 N/A

End Index Securities Investment

Fund

13Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

Agricultural Bank of China Co.Ltd. – CSI 500 Exchange-Traded

Open-End Index Securities Miscellaneous 0.71% 3021200.00 N/A

Investment Fund

Explanations of relationships Both Kunming Nuona Technology Co. Ltd. and Yunnan Haqisheng Enterprise Management

between or concerted actions of the Co. Ltd. are enterprises controlled by the Company’s actual controller Guo Zhenyu. Besides

aforementioned shareholders no connected relationship and action in concert between other shareholders is known to theCompany.The situation of shareholders holding more than 5% of shares the top 10 shareholders and the top

10 shareholders of unrestricted tradable shares participating in shares loan through refinancing

□ Applicable□Not applicable

Changes occurred in the top 10 shareholders and the top 10 shareholders of unrestricted tradable

shares compared with the previous period due to shares loan through refinancing/return

□ Applicable□Not applicable

Whether the Company has differential voting rights arrangements

□ Applicable□Not applicable

4.2 Total Number of Preferred Shareholders and Shareholding of the Top 10 Preferred

Shareholders

□Applicable□Not applicable

4.3 Disclosure of the Ownership and Control Relationship between the Company and the

Actual Controller in the Form of a Block Diagram

GUO ZHENYU

Hanson Cosmeceutical (Hong Kong) Company Limited

Outside the Chinese mainland (including Hong

Kong Macao and Taiwan)

Within the Chinese mainland (excluding

Hong Kong Macao and Taiwan) Kunming Nuona Technology Yunnan Haipo Enterprise Management Co. Ltd.Co. Ltd.Yunnan Haqisheng Enterprise Management Co.Ltd.Yunnan Botanee Bio-Technology Group Co. Ltd.

5. Bonds in Effect as of the Date of Approval of the Annual Report

□Applicable□Not applicable

14Yunnan Botanee Bio-Technology Group Co. Ltd. Summary of the 2025 Annual Report

III. Significant Matters

For details please refer to the 2025 Annual Report of Yunnan Botanee Bio-Technology Group Co.Ltd. (2026-013) disclosed on CNINFO (http://www.cninfo.com.cn).

15